Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases

Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients

(2015) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

SP0027 One for All – Patient Research Partners Involved in Disseminating Eular Recommendations Among Belgium Patients

(2015) I. De Keyser   ANNALS OF THE RHEUMATIC DISEASES

SAT0222 Effects of Tofacitinib on MRI Endpoints in Methotrexate-Naive Early Rheumatoid Arthritis: A Phase 2 MRI Study with Semi-Quantitative and Quantitative Endpoints

(2015) P.G. Conaghan et al.   ANNALS OF THE RHEUMATIC DISEASES

The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention

(2015) John J. O'Shea et al.   Annual Review of Medicine

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial

(2015) R. Bissonnette et al.   BRITISH JOURNAL OF DERMATOLOGY

Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer

(2015) Matteo Santoni et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tofacitinib for the treatment of moderate-to-severe psoriasis

(2015) Andrea Chiricozzi et al.   Expert Review of Clinical Immunology

Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis

(2015) Gareth W. Jones et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

(2015) Hervé Bachelez et al.   LANCET

The IL-23–IL-17 axis in inflammatory arthritis

(2015) Erik Lubberts   Nature Reviews Rheumatology

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

(2015) Joel M Kremer et al.   ARTHRITIS RESEARCH & THERAPY

Tofacitinib Citrate for the Treatment of Vitiligo

(2015) Brittany G. Craiglow et al.   JAMA Dermatology

Efficacy and Safety of Anti-Interleukin-20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial

(2015) Ladislav Šenolt et al.   Arthritis & Rheumatology

A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

(2015) Roy M. Fleischmann et al.   Arthritis & Rheumatology

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib

(2015) Christina Charles-Schoeman et al.   Arthritis & Rheumatology

Pharmacologic inhibition of JAK-STAT signaling promotes hair growth

(2015) S. Harel et al.   Science Advances

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

(2015) Ali Jabbari et al.   EBioMedicine

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia

(2014) Lisa Pieri et al.   AMERICAN JOURNAL OF HEMATOLOGY

OP0263 Efficacy and safety of GLPG0634, a selective JAK1 inhibitor, after short-term treatment of rheumatoid arthritis; results of a phase IIA trial

(2014) F.P. Vanhoutte et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

(2014) J. D. Milner et al.   BLOOD

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

(2014) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

(2014) Deepak Mittal et al.   CURRENT OPINION IN IMMUNOLOGY

Human IL-21 and IL-21R deficiencies

(2014) Daniel Kotlarz et al.   CURRENT OPINION IN PEDIATRICS

In Vivo Maintenance of Human Regulatory T Cells during CD25 Blockade

(2014) David J. Huss et al.   JOURNAL OF IMMUNOLOGY

Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis

(2014) Brittany G. Craiglow et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

(2014) J. Wollenhaupt et al.   JOURNAL OF RHEUMATOLOGY

Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

(2014) A. J. Gonzales et al.   JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

(2014) Gavin Giovannoni et al.   LANCET NEUROLOGY

White-to-brown metabolic conversion of human adipocytes by JAK inhibition

(2014) Annie Moisan et al.   NATURE CELL BIOLOGY

Covalent docking of large libraries for the discovery of chemical probes

(2014) Nir London et al.   Nature Chemical Biology

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE

Interleukin-21: a double-edged sword with therapeutic potential

(2014) Rosanne Spolski et al.   NATURE REVIEWS DRUG DISCOVERY

Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis

(2014) J. Oh et al.   NEUROLOGY

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remission of Recalcitrant Dermatomyositis Treated with Ruxolitinib

(2014) Thorsten Hornung et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activated STING in a Vascular and Pulmonary Syndrome

(2014) Yin Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective inhibition of the function of tyrosine-phosphorylated STAT3 with a phosphorylation site-specific intrabody

(2014) M. Y. Koo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human natural killer cell development in secondary lymphoid tissues

(2014) Aharon G. Freud et al.   SEMINARS IN IMMUNOLOGY

Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction

(2014) Claire J Greenhill et al.   ARTHRITIS RESEARCH & THERAPY

Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-Analysis

(2014) Alejandro Souto et al.   Arthritis & Rheumatology

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Janus kinase inhibitors in autoimmune diseases

(2013) John J O'Shea et al.   ANNALS OF THE RHEUMATIC DISEASES

Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

(2013) Joachim Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis

(2013) Ying He et al.   BMC MUSCULOSKELETAL DISORDERS

Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis

(2013) K. Migita et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome

(2013) Gulbu Uzel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mechanisms underlying helper T-cell plasticity: Implications for immune-mediated disease

(2013) Kiyoshi Hirahara et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases

(2013) Yasuaki Okuda et al.   Modern Rheumatology

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities

(2013) Jürgen Scheller et al.   SEMINARS IN IMMUNOLOGY

A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis

(2013) Sallie B. Cosgrove et al.   VETERINARY DERMATOLOGY

Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci

(2012) David Ellinghaus et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

(2012) F. Vincenti et al.   AMERICAN JOURNAL OF TRANSPLANTATION

IL-10 and IL-10 receptor defects in humans

(2012) Erik-Oliver Glocker et al.   Annals of the New York Academy of Sciences

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

(2012) Muriel Elhai et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

The interferon signature in autoimmune diseases

(2012) Lars Rönnblom et al.   CURRENT OPINION IN RHEUMATOLOGY

Interleukin-27: Balancing Protective and Pathological Immunity

(2012) Christopher A. Hunter et al.   IMMUNITY

Interleukin-27 Priming of T Cells Controls IL-17 Production In trans via Induction of the Ligand PD-L1

(2012) Kiyoshi Hirahara et al.   IMMUNITY

Increased Serum Interleukin 22 in Patients with Rheumatoid Arthritis and Correlation with Disease Activity

(2012) LAURINDO FERREIRA da ROCHA et al.   JOURNAL OF RHEUMATOLOGY

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease

(2012) Shiao Hui (Melissa) Liew et al.   OPHTHALMOLOGY

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

(2012) S. Unizony et al.   ARTHRITIS CARE & RESEARCH

Type I interferonopathies: a novel set of inborn errors of immunity

(2011) Yanick J. Crow   Annals of the New York Academy of Sciences

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

(2011) B. W. Higgs et al.   ANNALS OF THE RHEUMATIC DISEASES

Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease

(2011) Wenjun Ouyang et al.   Annual Review of Immunology

Increased levels of interleukin-27 in patients with rheumatoid arthritis

(2011) Hui Shen et al.   ARTHRITIS AND RHEUMATISM

Biologics-Based Therapy for the Treatment of Rheumatoid Arthritis

(2011) D L Scott   CLINICAL PHARMACOLOGY & THERAPEUTICS

Signaling by IL-31 and functional consequences

(2011) Christian Cornelissen et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-21 and IL-6 Are Critical for Different Aspects of B Cell Immunity and Redundantly Induce Optimal Follicular Helper CD4 T Cell (Tfh) Differentiation

(2011) Danelle Eto et al.   PLoS One

Therapeutic effect of tocilizumab on two patients with polymyositis

(2011) M. Narazaki et al.   RHEUMATOLOGY

Tocilizumab: a novel therapy for patients with large-vessel vasculitis

(2011) C. Salvarani et al.   RHEUMATOLOGY

Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050

(2010) J. S. Fridman et al.   JOURNAL OF IMMUNOLOGY

Increased Interleukin 21 (IL-21) and IL-23 Are Associated with Increased Disease Activity and with Radiographic Status in Patients with Early Rheumatoid Arthritis

(2010) T. K. RASMUSSEN et al.   JOURNAL OF RHEUMATOLOGY

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

(2010) Andre Franke et al.   NATURE GENETICS

The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling

(2010) Hergen Spits et al.   NATURE IMMUNOLOGY

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE